The Hatch-Waxman Act was enacted by Congress to encourage innovation in pharmaceutical research and development, and shorten the time to market for generic drugs. Fish’s award-winning life sciences practice has developed a four-part webinar series to examine and explain the Act in detail.

Chad Shear, an experienced life sciences trial lawyer, presented the first program in the series, Hatch-Waxman 101.

Introduce the Hatch-Waxman Act;
Explore the policy underpinning the Act;
Discuss the approval process and requirements; and
Examine how exclusivity works.

This complimentary webinar is perfect for those who have limited experience with the Hatch-Waxman Act. It will become the foundation for more advanced discussions in subsequent webinars in the series.

Hatch-Waxman 101

What VCs and PEs Need to Know About Patents

A Well-Crafted IP Strategy Will Take Small Defense Contractors Far

Texas Patent Litigation Monthly Wrap-Up: May 2024

Federal Circuit Reiterates That an Alleged Infringer’s Intent Is Irrelevant in a Hatch-Waxman Safe Harbor Analysis

Legal Alert: What the FTC’s Ban on Noncompete Agreements Means for Trade Secrets

Hatch-Waxman 101

Biologics and Biosimilars Landscape: IP, Policy, and Market Developments

ITC Monthly Wrap-Up: February 2024

ITC Monthly Wrap-Up: January 2024

Texas Patent Litigation Monthly Wrap-Up: December 2023

Hatch-Waxman 2023 Year in Review